June 13, 2011 (Washington, DC) — Data from 64 HeartMate II (Thoratec) left ventricular assist device (LVAD) patients treated at the Henry Ford Hospital in Detroit suggest that many of the patients ...
PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...
In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...
Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3
ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...
SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...
Thoratec's HeartMate II left ventricular assist device--Courtesy of Thoratec Thoratec ($THOR) said that two patients died and one suffered a serious injury after they ...
NEW YORK (April 25, 2008) -- Heart failure patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first to be implanted with the HeartMate® II LVAS (Left ...
Thoratec shed almost one-third of its value after reporting abysmal second quarter earnings. The advanced heart failure device company attributed most of the miss to a New England Journal of Medicine ...
MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...
Shares of St. Jude Medical Inc.STJ rose nearly 2.2% yesterday, following the CE Mark approval for HeartMate 3 Left Ventricular Assist System (LVAS) in Europe. The company will start to commercialize ...
March 12 (UPI) --The HeartMate 3, an update to one of the most widely-used left ventricle assist devices, or LVADs, in the world, showed strong long-term results during a large clinical trial, its ...
Thoratec Corp ( THOR) recently completed enrollment of 50 patients under the HeartMate III CE Mark trial at ten sites across Europe, Canada and Australia. The trial will monitor these patients over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback